All News
Performance BASDAI & ASDAS in evaluating PsA axial symptoms?
400+ pts DISCOVER 1&2
Weak correlations w/ peripheral arthritis
Moderate/strong correlations w/ fatigue & pain
Both perform similarly but do they perform well enough?
https://t.co/alnrEXtydp
Abs#1037 #ACR22 @Rheumnow https://t.co/Zuf1FruneK
Aurelie Najm AurelieRheumo ( View Tweet)
Benefits with receiving anabolic agents upfront before antiresoprtives (as opposed to other way around). Shame about lack of access to this sequence currently
@RheumNow #ACR22 #osteoporosis https://t.co/S2ttbrVaab
Julian Segan JulianSegan ( View Tweet)
Low likelihood of syndesmophyte formation in PsA but is more likely assoc'd w/ axial involvement radiographically + high CRP. Abs 1014 #ACR22 @RheumNow https://t.co/M5Tc0fd64s https://t.co/e25gwVQKeo
Dr. Rachel Tate uptoTate ( View Tweet)
DISCOVER 1 & 2: Subanalysis of GUS in 181 pts w/ Axial PsA and imaging confirmed SI
GUS improves BASDAI, mBASDAI, spinal pain, morning stiffness, and ASDAS from W8 to W24
W24 Response rates BASDAI50 38% BASDAI70 20%
https://t.co/MrS8atrIOI
Abs#1035 #ACR22 @Rheumnow https://t.co/wMDkO1Qak9
Aurelie Najm AurelieRheumo ( View Tweet)
Most important point from the Great Debate on treating pre-RA.
Are we really treating to prevent RA or are we simply delaying RA onset?
I don't think there is enough data to treat pre-clinical RA with our current arsenal of DMARDs.
What would you do?
@RheumNow #ACR22
Robert B Chao, MD doctorRBC ( View Tweet)
The Great Debate! Should you treat pre-clinical RA?
ACPA+ ~40% did not convert to clinical RA
RF+/ACPA+ least likely to seroconvert to negative
@RheumNow #ACR22 https://t.co/djVPKDdWjz
Robert B Chao, MD doctorRBC ( View Tweet)
Dr. Talabi: Progestin-only has⬇️thrombotic risk vs. estrogen👇
‼️Safety signal for DMPA/depo shot bec. might be more prothrombotic vs. other progestin methods; addt'l studies needed; recommend to avoid in aPL+ for now
#ACR22 @Rheumnow https://t.co/pQe5H8wqvi
sheila RHEUMarampa ( View Tweet)
"Less than 1 in 6 rheumatology guideline recommendations are informed by head-to-head RCTs." #ACR22 abst#1284 @rheumnow Comparative Effectiveness Randomized Controlled Trials in Rheumatology Guidelines https://t.co/l5NzzcHRSA
TheDaoIndex KDAO2011 ( View Tweet)
Most prevalent locations of enthesitis on the global SpA population are the lumbar spinous processes, the thoracic spinous processes & Achilles tendon. MEI & MASES best capturing axSpA enthesitis. MEI & SPARCC best in pSpA & PsA. Abs 1004 #ACR22 @RheumNow https://t.co/6IbusqHI5d https://t.co/5y5NFthyJz
Dr. Rachel Tate uptoTate ( View Tweet)
Tofacitinib in new-onset PMR:
Nice mechanistic data - all the right things line up - leading to promising proof-of-concept study (EAST PMR)
Plenty to tease apart here but real promise to explore in bigger studies
ABST1107 #ACR22 @RheumNow https://t.co/s4ts7lrVtZ
David Liew drdavidliew ( View Tweet)
Dr Iyer shares how ROSCE can teach trainees #telerheumatology using video visits:
☝️ Relevant to career, enhanced self-directed learning
☝️Accdg to ROSCE results, improvement needed on telemed focused exams
🤓Video ROSCE as T-L strat, eval
#ACR22 @RheumNow #MedEd @rheumarhyme https://t.co/kZXMrbwtzW
sheila RHEUMarampa ( View Tweet)
Coming off denosumab is very tricky! No such thing as drug holiday given high risk of rebound fractures. Need to cap with BP but duration uncertain.
@RheumNow #ACR22 #osteoporosis https://t.co/a4VNAI2D49
Julian Segan JulianSegan ( View Tweet)
Was my pleasure to chat with Prof Eder @lihi_eder about her fantastic abstract #1007 about dietary interventions in PsA- DIPSA study!
Catch our interview now on below link 🌟
#ACR22 @RheumNow
https://t.co/liwc38wErT
Patricia Harkins DrTrishHarkins ( View Tweet)
Abs 1008 at #ACR22 shows endothelial dysfunction found in SpA pts assoc'd with worsening mSASSS, time of disease evolution, BASMI and BASFI, and CV plaques in axSpA. @RheumNow https://t.co/7Zxl4PcPfR https://t.co/3cAqigHtNU
Dr. Rachel Tate uptoTate ( View Tweet)
The great debate
Pre-RA to treat or not to treat?
@HaniElgabalawy @Janetbirdope
What a conversation with a patient at-risk of RA would look like based on current literature.
Would you suggest to treat?
If I was Mr Jones, I wouldn’t buy it.
#ACRdebate #ACR22 @RheumNow https://t.co/vEj4KOauzz
Aurelie Najm AurelieRheumo ( View Tweet)
Abstr #1037 evaluated BASDAI vs ASDAS in PsA w/ axial dx
Both ASDAS & BASDAI showed
- strong correlation w/ pt pain & Global Assessment
- weak correlation in tender and swollen joint counts and enthesitis
#ACR22 @RheumNow #axSpA #PsA https://t.co/EunXIwzn3M
Akhil Sood MD AkhilSoodMD ( View Tweet)
The Great Debate! Should you treat pre-clinical RA?
US erosions in 5th MTPs predict clinical arthritis in +CCP "Pre-RA" patients
~15% of patients will develop RA
@RheumNow #ACR22 https://t.co/jS2YMlF4iO
Robert B Chao, MD doctorRBC ( View Tweet)
Danish registry, 11000+ pts w/ sarcoidosis:
> incidence young males
> IR if born after 1976 in males IRR 1.22, no diff in females
1976 = yr systematic BCG vaccination stopped
Attributed to ↘️ intake BCG vax
Underlying mechanism?
https://t.co/At3dUwIgES
Abs#1111 #ACR22 @Rheumnow https://t.co/gArfdAVapD
Aurelie Najm AurelieRheumo ( View Tweet)
The Great Debate! Should you treat pre-clinical RA?
"The more good factors you have, the less likely you will develop RA"
- Janet Pope
Never smoker, normal BMI, low EtOH, exercise, healthy diet
@RheumNow #ACR22 https://t.co/jIMOn8ht6u
Robert B Chao, MD doctorRBC ( View Tweet)
70% of #AOSD pts were females! Large HCA database study - incidence rate - 0.16 - 0.21 per 100,000 (similar to French studies).
24% required ICU level of care, 12% had PNA (fig)
Mortality is higher than other cohorts - 3.2%
#ACR22 @RheumNow abst#0829 https://t.co/fcFUnExYOE
Bella Mehta bella_mehta ( View Tweet)